Literature DB >> 18097110

Retrospective study of severe cases of leptospirosis admitted in the intensive care unit.

A M Ittyachen1, T V Krishnapillai, M C Nair, A R Rajan.   

Abstract

OBJECTIVES: Evaluate patient demographics, risk factors, complications, seropositivity, treatment and outcome among leptospirosis patients.
DESIGN: Retrospective analysis of 104 patients admitted in the intensive care unit (ICU) with a clinical suspicion of leptopirosis.
SETTING: Ten-bedded medical ICU in a medical school situated in a rural area endemic for leptospirosis. MAIN OUTCOME MEASURES: Seropositivity for leptospirosis, patient demographics, risk factors, complications, treatment and survival.
RESULTS: One hundred and four patients were admitted with a clinical suspicion of leptospirosis. Fifty-three (50.7%) were serologically confirmed cases. Males dominated both groups. Most of the admissions were in the monsoon season. Exposure to moist soil was the main risk factor. The mortality in the seronegative group was 26.8% while it was only 3.8% in the seropositive group. Multi-organ dysfunction syndrome, primarily acute respiratory distress syndrome with thromboctyopenia and renal failure were the causes for mortality. All the patients who died presented late into the illness.
CONCLUSIONS: The initial diagnosis of leptospirosis depends on a high index of clinical suspicion, routinely available diagnostic tests being unreliable in the initial period. A reliable, unsophisticated test should be developed for early detection of this disease. As leptospirosis in its early stage mimics other tropical infections, both medical professionals and the general public (especially with risk of occupational exposure) should be educated about the disease and the need to seek early medical intervention.

Entities:  

Mesh:

Year:  2007        PMID: 18097110     DOI: 10.4103/0022-3859.37510

Source DB:  PubMed          Journal:  J Postgrad Med        ISSN: 0022-3859            Impact factor:   1.476


  8 in total

1.  Determinants of mortality and impact of therapy in patients with leptospirosis admitted for intensive care in a Sri Lankan hospital--a three year retrospective study.

Authors:  P N Weeratunga; S Fernando; S Sriharan; M Gunawardena; S Wijenayake
Journal:  Pathog Glob Health       Date:  2015       Impact factor: 2.894

Review 2.  Community-acquired acute kidney injury in tropical countries.

Authors:  Vivekanand Jha; Sreejith Parameswaran
Journal:  Nat Rev Nephrol       Date:  2013-03-05       Impact factor: 28.314

3.  Commonly used severity scores are not good predictors of mortality in sepsis from severe leptospirosis: a series of ten patients.

Authors:  Dimitrios Velissaris; Menelaos Karanikolas; Nikolaos Flaris; Fotini Fligou; Markos Marangos; Kriton S Filos
Journal:  Crit Care Res Pract       Date:  2012-05-21

4.  Acute respiratory distress syndrome: A study of autopsy findings.

Authors:  Anurag Saha; Gayathri P Amonkar; Heena Desai; Bhanita Baro; Ruchi Agrawal
Journal:  Lung India       Date:  2021 Sep-Oct

5.  Determinants of prolonged hospitalization and mortality among leptospirosis patients attending tertiary care hospitals in northeastern state in peninsular Malaysia: A cross sectional retrospective analysis.

Authors:  Yassin K Al Hariri; Syed A S Sulaiman; Amer H Khan; Azreen S Adnan; Sundos Q Al-Ebrahem
Journal:  Front Med (Lausanne)       Date:  2022-09-09

6.  Increasing trends of leptospirosis in northern India: a clinico-epidemiological study.

Authors:  Sunil Sethi; Navneet Sharma; Nandita Kakkar; Juhi Taneja; Shiv Sekhar Chatterjee; Surinder Singh Banga; Meera Sharma
Journal:  PLoS Negl Trop Dis       Date:  2010-01-12

7.  The course and outcome of renal failure due to human leptospirosis referred to a hospital in North of Iran; A follow-up study.

Authors:  Roya Ghasemian; Mehran Shokri; Atieh Makhlough; Mohammad Amin Suraki-Azad
Journal:  Caspian J Intern Med       Date:  2016

8.  Leptospirosis in Intensive Care Unit.

Authors:  Niteen D Karnik; Aditi S Patankar
Journal:  Indian J Crit Care Med       Date:  2021-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.